Advanced search
Publication Cover
Expert Opinion on Emerging Drugs Volume 14, 2009 - Issue 1
Submit an article Journal homepage
204
Views
7
CrossRef citations to date
0
Altmetric
Review

Emerging drugs for psoriasis

Luigi Naldi Centro Studi GISED; Department of Dermatology, Ospedali Riuniti, Largo Barozzi 1, 24100 Bergamo, Italy +39 035400625; +39 035266458; [email protected]
, MD &
Giovanna Raho Centro Studi GISED
, Sc Biol
Pages 145-163 | Published online: 27 Feb 2009

Bibliography

  • Schoen MP, Boehnicke WH. Psoriasis. N Engl J Med 2005;352:1899-912
  • Iizuka H, Takahashi H, Ishida-Yamamoto A. Psoriatic architecture constructed by epidermal remodeling. J Dermatol Sci 2004;35:93-9
  • Naldi L, Gambini D. The clinical spectrum of psoriasis. Clin Dermatol 2007;25:510-8
  • Balasubramaniam P, Berth-Jones J. Erythroderma: 90% skin failure. Hosp Med 2004;65:100-2
  • Jackson R. The importance of being visually literate: observations on the art and science of making a morphological diagnosis in dermatology. Arch Dermatol 1975;111:632-6
  • Jobling R, Naldi L. Assessing the impact of psoriasis and the relevance of qualitative research. J Invest Dermatol 2006;126:1438-40
  • Coates LC, Helliwell PS. Classification and categorisation of psoriatic arthritis. Clin Rheumatol 2008;27:1211-6.
  • Bernstein CN, Wajda A, Blanchard JF. The clustering of other chronic inflammatory diseases in inflammatory bowel disease: a population-based study. Gastroenterology 2005;129:827-36
  • Azfar RS, Gelfand JM. Psoriasis and metabolic disease: epidemiology and pathophysiology. Curr Opin Rheumatol 2008;20:416-22
  • Mantovani A. Inflaming metastasis. Nature 2009;457:36-7
  • Kimball AB, Robinson D Jr, Wu Y Cardiovascular disease and risk factors among psoriasis patients in two US healthcare databases, 2001-2002. Dermatology 2008;217:27-37
  • Boffetta P, Gridley G, Lindelof B. Cancer risk in a population-based cohort of patients hospitalized for psoriasis in Sweden. J Invest Dermatol 2001;117:1531-7
  • Olsen JH, Møller H, Frentz G. Malignant tumors in patients with psoriasis. J Am Acad Dermatol 1992;27:716-22
  • Gelfand JM, Berlin J, Van Voorhees A, Margolis DJ. Lymphoma rates are low but increased in patients with psoriasis: results from a population-based cohort study in the United Kingdom. Arch Dermatol 2003;139:1425-9
  • Bell LM, Sedlack R, Beard MC, et al. Incidence of psoriasis in Rochester, Minn 1980-1983. Arch Dermatol 1991;127:1184-7
  • Huerta C, Rivero E, Rodríguez LA. Incidence and risk factors for psoriasis in the general population. Arch Dermatol 2007;143:1559-65
  • Naldi L. Epidemiology of psoriasis. Curr Drug Targets Inflamm Allergy 2004;3:121-8
  • Andressen C, Henseler T. Inheritance of psoriasis. Analysis of 2035 family histories. Hautarzt 1982;33:214-7
  • Duffin KC, Chandran V, Gladman DD, et al. Genetics of psoriasis and psoriatic arthritis: update and future direction. J Rheumatol 2008;35:1449-53
  • Valdimarsson H. The genetic basis of psoriasis. Clin Dermatol 2007;25:563-7
  • Setty AR, Curhan G, Choi HK. Smoking and the risk of psoriasis in women: Nurses' Health Study II. Am J Med 2007;120:953-9
  • Setty AR, Curhan G, Choi HK. Obesity, waist circumference, weight change, and the risk of psoriasis in women. Arch Intern Med 2007;167:1670-5
  • Henseler T, Christophers E. Psoriasis of early and late onset: characterization of two types of psoriasis vulgaris. J Am Acad Dermatol 1985;13:450-6
  • EMEA Committee for Proprietary Medical Products. Note for guidance on clinical investigation of medical products indicated for the treatment of psoriasis. CPMP/EWP 2454/02
  • Schmid-Ott G, Schallmayer S, Calliess IT. Quality of life in patients with psoriasis and psoriasis arthritis with a special focus on stigmatization experience. Clin Dermatol 2007;25:547-54
  • Sampogna F, Sera F, Abeni D. Measures of clinical severity, quality of life, and psychological distress in patients with psoriasis: a cluster analysis. J Invest Dermatol 2004;122:602-7
  • Schmitt J, Wozel G. The psoriasis area and severity index is the adequate criterion to define severity in chronic plaque-type psoriasis. Dermatology 2005;210:194-9
  • Unaeze J, Nijsten T, Murphy A, et al. Impact of psoriasis on health-related quality of life decreases over time: an 11-year prospective study. J Invest Dermatol 2006;126:1480-9
  • Farber EM, Nall L. The natural history of psoriasis in 5,600 patients. Dermatologica 1974;148:1-18
  • Naldi L, Colombo P, Benedetti Placchesi E, et al. Study design and preliminary results from the pilot phase of the PraKtis study: self-reported diagnoses of selected skin diseases in a representative sample of the Italian population. Dermatology 2004;208:38-42
  • Menter A, Griffiths CEM. Current and future management of psoriasis. Lancet 2007;370:272-84
  • Naldi L, Minelli C. Dermatology. In: Machin D, Day S, Green S, editors, Textbook of clinical trials. John Wiley and sons, Ltd, Chichester, England 2006. p 263-85
  • Lambert MF, Wood J. Incorporating patient preferences into randomized trials. J Clin Epidemiol 2000;53:163-6
  • Van de Kerkhof PCM, De Hoop D, De Korte J, et al. Patient compliance and disease management in the treatment of psoriasis in the Netherlands. Dermatology 2000;200:292-8
  • Naldi L, Rzany B. Chronic plaque psoriasis. Clin Evid 2006;15:2249-83
  • Katz KA. ‘Biologics’: a clinically meaningless term. Br J Dermatol 2006;154:809-12
  • Mason J, Mason AR, Cork MJ. Topical preparations for the treatment of psoriasis: a systemic review. Br J Dermatol 2002;146:351-64
  • Bruner CR, Feldman SR, Ventrapragada M, Fleischer AB Jr. A systematic review of adverse effects associated with topical treatments for psossriasis. Dermatol Online J 2003;9:2
  • Nast A, Kopp I, Augustin M, et al. German evidence-based guidelines for the treatment of Psoriasis vulgaris (short version). Arch Dermatol Res 2007;299:111-38
  • Ashcroft DM, Po AL, Williams HC, Griffiths CEM. Systematic review of comparative efficacy and tolerability of calcipotriol in treating chronic plaque psoriasis. BMJ 2000;320:963-67
  • Stern RS. Psoralen and ultraviolet a light therapy for psoriasis. N Engl J Med 2007;357:682-90
  • Ibbotson SH, Bilsland D, Cox NH, et al. An update and guidance on narrowband ultraviolet B phototherapy: a British Photodermatology Group Workshop Report. Br J Dermatol 2004;151:283-97
  • Taibjee SM, Cheung ST, Laube S, Lanigan SW. Controlled study of excimer and pulsed dye lasers in the treatment of psoriasis. Br J Dermatol 2005;153:960-66
  • Viola G, Fortunato E, Cecconet L, et al. Central role of mitochondria and p53 in PUVA-induced apoptosis in human keratinocytes cell line NCTC-2544. Toxicol Appl Pharmacol 2008;227:84-96
  • Hannuksela-Svahn A, Sigurgeirsson B, Pukkala E, et al. Trioxsalen bath PUVA did not increase the risk of squamous cell skin carcinoma and cutaneous malignant melanoma in a joint analysis of 944 Swedish and Finnish patients with psoriasis. Br J Dermatol 1999;141:497-501
  • Griffiths CEM, Clark CM, Chalmers RJ, et al. A systematic review of treatments for severe psoriasis. Health Technol Assess 2000;4:1-125
  • Naldi L, Griffiths CME. Traditional therapies in the management of moderate to severe chronic plaque psoriasis: an assessment of the benefits and risks. Br J Dermatol 2005;152:597-615
  • Heydendael VM, Spuls PI, Opmeer BC, et al. Methotrexate versus ciclosporin in moderate-to severe chronic plaque psoriasis. N Engl J Med 2003;349:658-65
  • Saurat JH, Stingl G, Dubertret L, et al. Efficacy and safety results from the randomized controlled comparative study of adalimumab vs. methotrexate vs. placebo in patients with psoriasis (CHAMPION). Br J Dermatol 2008;158:558-66
  • Griffiths CEM, Dubertret L, Ellis CN, et al. Ciclosporin in psoriasis clinical practice: an international consensus statement. Br J Dermatol 2004;150:11-23
  • Paul CF, Ho VC, McGeown C, et al. Risk of malignancies in psoriasis patients treated with ciclosporin: a 5 y cohort study. J Invest Dermatol 2003;120:211-16
  • Treumer F, Zhu K, Glaser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol 2003;121:1383-88
  • Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein b in activated human T cells. Br J Dermatol 2007;156:838-42
  • Tang H, Lu JY, Zheng X, et al. The psoriasis drug monomethylfumarate is a potent nicotinic acid receptor agonist. Biochem Biophys Res Commun 2008;375:562-5.
  • Mrowietz U, Altmeyer P, Bieber T, et al. Treatment of psoriasis with fumaric acid esters (Fumaderm). J Dtsch Dermatol Ges 2007;5:716-7
  • Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol 2003;149:363-69
  • Smith CH, Anstey AV, Barker JN, et al. British Association of Dermatologists. British Association of Dermatologists guidelines for use of biological interventions in psoriasis 2005. Br J Dermatol 2005;153:486-97
  • Woolacott N, Hawkins N, Mason A, et al. Etanercept and efalizumab for the treatment of psoriasis: a systematic review. Health Technol Assess 2006;10(46):1-233, i-iv
  • Bongartz T, Sutton AJ, Sweeting MJ, et al. Anti-TNF antibody therapy in rheumatoid arthritis and the risk of serious infections and malignancies: systematic review and meta-analysis of rare harmful effects in randomized controlled trials. JAMA 2006;295:2275-85
  • Flendrie M, Vissers WHPM, Creemers MCW, et al. Dermatological conditions during TNF-α-blocking therapy in patients with rheumatoid arthritis: a prospective study. Arthritis Res Ther 2005;7:R666-76 (DOI 10.1186/ar1724)
  • Carey W, Glazer S, Gottlieb AB, et al. Relapse, rebound, and psoriasis adverse events: an advisory group report. J Am Acad Dermatol 2006;54:s171-81
  • Gisondi P, Del Giglio M, Cotena C, Girolomoni GP. Combining etanercept and acitretin in the therapy of chronic plaque psoriasis: a 24-week, randomized, controlled, investigator-blinded pilot trial. Br J Dermatol 2008;158:1345-9
  • Krueger GG. Current concepts and review of alefacept in the treatment of psoriasis. Dermatol Clin 2004;22:407-26
  • Ellis CN, Krueger GG, for the Alefacept Clinical Study Group. Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes. N Engl J Med 2001;345:248-55
  • Leonardi CL. Current concepts and review of efalizumab in the treatment of psoriasis. Dermatol Clin 2004;22:427-35
  • Yamauchi PS, Gindi V, Lowe NJ. The treatment of psoriasis and psoriatic arthritis with etanercept: practical considerations on monotherapy, combination therapy, and safety. Dermatol Clin 2004;22:449-59
  • Leonardi CL, Powers JL, Matheson RT, et al. Etanercept as monotherapy in patients with psoriasis. N Engl J Med 2003;349:2014-22
  • Tyring S, Gottlieb A, Papp K, et al. Etanercept and clinical outcomes, fatigue, and depression in psoriasis: double-blind placebo-controlled randomised phase III trial. Lancet 2006;367:29-35
  • Winterfield L, Menter A. Psoriasis and its treatment with infliximab-mediated tumor necrosis factor alpha blockade. Dermatol Clin 2004;22:437-47
  • Chaudhari U, Romano P, Mulcahy LD, et al. Efficacy and safety of infliximab monotherapy for plaque-type psoriasis: a randomised trial. Lancet 2001;357:1842-47
  • Reich K, Nestle FO, Papp K, et al. Infliximab induction and maintenance therapy for moderate-to-severe psoriasis: a phase III, multicentre, double-blind trial. Lancet 2005;366:1367-74
  • Menter A, Feldman SR, Weinstein GD, et al. A randomized comparison of continuous vs. intermittent infliximab maintenance regimens over 1 year in the treatment of moderate-to-severe plaque psoriasis. J Am Acad Dermatol 2007;5631:e1-15
  • Gordon KB, Langley RG, Leonardi C, et al. Clinical response to adalimumab treatment in patients with moderate to severe psoriasis: double-blind randomized controlled trial and open label extension study. J Am Acad Dermatol 2006;55:598-606
  • Menter A, Tyring SK, Gordon K, et al. Adalimumab therapy for moderate to severe psoriasis: a randomized, controlled phase III trial. J Am Acad Dermatol 2008;58:106-15
  • Naldi L, Svensson A, Diepgen T, et al. Randomized clinical trials for psoriasis 1977-2000: the EDEN survey. J Invest Dermatol 2003;120:738-41
  • Kalorama Information. The Worldwide Market for prescription dermatological drugs, Fourth edition, February 2004, Kalorama Infornation, New York.
  • Nickoloff BJ, Nestle FO. Recent insights into the immunopathogenesis of psoriasis provide new therapeutic opportunities. J Clin Invest 2004;113:1664-75
  • Lowes MA, Bowcock AM, Krueger JG. Pathogenesis and therapy of psoriasis. Nature 2007;455:866-73
  • Gaspari AA. Innate and adaptive immunity and the pathophysiology of psoriasis. J Am Acad Dermatol 2006;54:S67-80
  • Griffiths CE, Barker JN. Pathogenesis and clinical features sof psoriasis. Lancet 2007;370:263-71
  • Li A, Simmons PJ, Kaur P. Identification and isolation of candidate human keratinocyte stem cells based on cell surface phenotype. Proc Natl Acad Sci USA 1998;95:3902-7
  • Nestle FO, Conrad C, Tun-Kyi A, et al. Plasmacytoid predendritic cells initiate psoriasis through interferon-alpha production. J Exp Med 2005;202:135-43
  • Mosmann TR, Coffman RL. TH1 and TH2 cells: different patterns of lymphokine secretion lead to different functional properties. Annu Rev Immunol 1989;7:145-73
  • Tschachler E. Psoriasis: the epidermal component. Clin Dermatol 2007;25:589-95
  • Nickoloff BJ. Keratinocytes regain momentum as instigators of cutaneous inflammation. Trends Mol Med 2006;12:102-6
  • Zenz R, Eferl R, Kenner L, et al. Psoriasis-like skin disease and arthritis caused by inducible epidermal deletion of Jun proteins. Nature 2005;437(7057):369-75
  • Boniface K, Guignouard E, Pedretti N, et al. A role for T cell-derived interleukin 22 in psoriatic skin inflammation. Clin Exp Immunol 2007;150:407-15
  • Zheng Y, Danilenko DM, Valdez P, et al. Interleukin-22, a T(H)17 cytokine, mediates IL-23-induced dermal inflammation and acanthosis. Nature 2007;445:648-51
  • Available from: http://www.clinicaltrials.gov/
  • Hutas G. Golimumab, a fully human monoclonal antibody against TNFalpha. Curr Opin Mol Ther 2008;10:393-406
  • Melmed GY, Targan SR, Yasothan U, et al. Certolizumab pegol. Nat Rev Drug Discov 2008;7:641-2
  • Krueger GG, Langley RG, Leonardi C, et al. A human interleukin 12/23 antibody for the treatment of psoriasis. N Engl J Med 2007;356:580-92
  • Papp KA, Langley RG, Lebwohl M, et al. PHOENIX 2 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 52-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 2). Lancet 2008;371:1675-84
  • Leonardi CL, Kimball AB, Papp KA, et al. PHOENIX 1 study investigators. Efficacy and safety of ustekinumab, a human interleukin-12/23 monoclonal antibody, in patients with psoriasis: 76-week results from a randomised, double-blind, placebo-controlled trial (PHOENIX 1). Lancet 2008;371:1665-74
  • Kimball AB, Gordon KB, Langley RG, et al. ABT-874 Psoriasis Study Investigators. Safety and efficacy of ABT-874, a fully human interleukin 12/23 monoclonal antibody, in the treatment of moderate to severe chronic plaque psoriasis: results of a randomized, placebo-controlled, phase 2 trial. Arch Dermatol 2008;144:200-7
  • Wakkee M, Thio HB. Drug evaluation: BG-12, an immunomodulatory dimethylfumarate. Curr Opin Investig Drugs 2007;8:955-62
  • Papp K, Bissonette R, Rosoph L, et al. Efficacy of ISA247 in plaque psoriasis: a randomised, multicentre, double-blind, placebo-controlled phase III study. Lancet 2008;371:1337-42
  • Verfaille CJ, Thissen CA, Bovenschen HJ, et al. Oral R115866 in the treatment of moderate to severe plaque-type psoriasis. J Eur Acad Dermatol Venereol 2007;21:1038-46
  • Bar-Yehuda S, Silverman MH, Kerns WD, et al. The anti-inflammatory effect of A3 adenosine receptor agonists: a novel targeted therapy for rheumatoid arthritis. Expert Opin Investig Drugs 2007;16:1601-13
  • Giembycz MA. Can the anti-inflammatory potential of PDE4 inhibitors be realized: guarded optimism or wishful thinking? Br J Pharmacol 2008;155:288-90.
  • Schieven GL. The biology of p38 kinase: a central role in inflammation. Curr Top Med Chem 2005;5:921-8
  • Tickenbrock L, Müller-Tidow C, Berdel WE, Serve H. Emerging Flt3 kinase inhibitors in the treatment of leukaemia. Expert Opin Emerg Drugs 2006;11:153-65
  • Deuse T, Velotta JB, Hoyt G, et al. Novel immunosuppression: R348, a JAK3- and Syk-inhibitor attenuates acute cardiac allograft rejection. Transplantation 2008;85:885-92
  • Skvara H, Dawid M, Kleyn E, et al. The PKC inhibitor AEB071 may be a therapeutic option for psoriasis. J Clin Invest 2008;118:3151-9
  • Kurd SK, Smith N, VanVoorhees A, et al. Oral curcumin in the treatment of moderate to severe psoriasis vulgaris: A prospective clinical trial. J Am Acad Dermatol 2008;58:625-31
  • Williams B, Vanags D, Hall S, et al. Efficacy and safety of chaperonin 10 in patients with moderate to severe plaque psoriasis: evidence of utility beyond a single indication. Arch Dermatol 2008;144:683-5
  • Campalani E, Arenas M, Marinaki AM, et al. Polymorphisms in folate, pyrimidine and purine metabolism are associated with efficacy and toxicity of methotrexate in psoriasis. J Invest Dermatol 2007;127:1860-7.
  • De Vlam K, Gottlieb AB, Fitzgerald O. Biological biomarkers in psoriatic disease. A review. J Rheumatol 2008;35:1443-8
  • Lecluse LL, Naldi L, Stern RS, Spuls PI. National registries of systemic treatment for Psoriasis and the European ‘Psonet’ initiative. Dermatology 2008 [Epub ahead of print]

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.